These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33832284)
1. The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review. Long Y; Tang Y; Cai C; Yu M; Zhang M; Chen R; Huang M Ann Palliat Med; 2021 Jun; 10(6):7088-7094. PubMed ID: 33832284 [TBL] [Abstract][Full Text] [Related]
2. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286 [TBL] [Abstract][Full Text] [Related]
3. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? Di Federico A; De Giglio A; Parisi C; Gelsomino F Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370 [TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912 [TBL] [Abstract][Full Text] [Related]
5. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679 [TBL] [Abstract][Full Text] [Related]
6. Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. Hasegawa T; Yanagitani N; Ninomiya H; Sakamoto H; Tozuka T; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Ariyasu R; Uchibori K; Kitazono S; Horiike A; Nishio M In Vivo; 2020; 34(5):2997-3003. PubMed ID: 32871843 [TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Xia L; Liu Y; Wang Y Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Dafni U; Tsourti Z; Vervita K; Peters S Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971 [TBL] [Abstract][Full Text] [Related]
14. Emerging Therapeutic Implications of STK11 Mutation: Case Series. Laderian B; Mundi P; Fojo T; E Bates S Oncologist; 2020 Sep; 25(9):733-737. PubMed ID: 32396674 [TBL] [Abstract][Full Text] [Related]
15. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570 [TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
17. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602 [TBL] [Abstract][Full Text] [Related]
18. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience. Torralvo J; Friedlaender A; Achard V; Addeo A Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221 [TBL] [Abstract][Full Text] [Related]
20. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]